Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
10.1038/nature10003
Crossref journal-article
Springer Science and Business Media LLC
Nature (297)
Bibliography

Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A. W., Chiuchiolo, M. J., Parks, C. L., Axthelm, M. K., Nelson, J. A., Jarvis, M. A., Piatak, M., Lifson, J. D., & Picker, L. J. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature, 473(7348), 523–527.

Authors 19
  1. Scott G. Hansen (first)
  2. Julia C. Ford (additional)
  3. Matthew S. Lewis (additional)
  4. Abigail B. Ventura (additional)
  5. Colette M. Hughes (additional)
  6. Lia Coyne-Johnson (additional)
  7. Nathan Whizin (additional)
  8. Kelli Oswald (additional)
  9. Rebecca Shoemaker (additional)
  10. Tonya Swanson (additional)
  11. Alfred W. Legasse (additional)
  12. Maria J. Chiuchiolo (additional)
  13. Christopher L. Parks (additional)
  14. Michael K. Axthelm (additional)
  15. Jay A. Nelson (additional)
  16. Michael A. Jarvis (additional)
  17. Michael Piatak (additional)
  18. Jeffrey D. Lifson (additional)
  19. Louis J. Picker (additional)
References 36 Referenced 865
  1. Grovit-Ferbas, K., Pappas, T. & O’Brien, W. A. in Persistent Viral Infections (eds Ahmed, R. & Chen, A. I. ) 3–45 (John Wiley & Sons, 1999) / Persistent Viral Infections by K Grovit-Ferbas (1999)
  2. Haase, A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nature Rev. Immunol. 5, 783–792 (2005) (10.1038/nri1706) / Nature Rev. Immunol. by AT Haase (2005)
  3. Goulder, P. J. & Watkins, D. I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nature Rev. Immunol. 8, 619–630 (2008) (10.1038/nri2357) / Nature Rev. Immunol. by PJ Goulder (2008)
  4. Haase, A. T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217–223 (2010) (10.1038/nature08757) / Nature by AT Haase (2010)
  5. Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293–299 (2009) (10.1038/nm.1935) / Nature Med. by SG Hansen (2009)
  6. Robinson, H. L. & Amara, R. R. T cell vaccines for microbial infections. Nature Med. 11, S25–S32 (2005) (10.1038/nm1212) / Nature Med. by HL Robinson (2005)
  7. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552–7557 (2008) (10.1073/pnas.0802203105) / Proc. Natl Acad. Sci. USA by BF Keele (2008)
  8. Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869–8873 (1998) (10.1073/pnas.95.15.8869) / Proc. Natl Acad. Sci. USA by TW Chun (1998)
  9. Bachmann, M. F., Kundig, T. M., Hengartner, H. & Zinkernagel, R. M. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without “memory T cells”? Proc. Natl Acad. Sci. USA 94, 640–645 (1997) (10.1073/pnas.94.2.640) / Proc. Natl Acad. Sci. USA by MF Bachmann (1997)
  10. Ochsenbein, A. F. et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc. Natl Acad. Sci. USA 96, 9293–9298 (1999) (10.1073/pnas.96.16.9293) / Proc. Natl Acad. Sci. USA by AF Ochsenbein (1999)
  11. Casimiro, D. R. et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547–15555 (2005) (10.1128/JVI.79.24.15547-15555.2005) / J. Virol. by DR Casimiro (2005)
  12. Letvin, N. L. et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530–1533 (2006) (10.1126/science.1124226) / Science by NL Letvin (2006)
  13. Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875–5885 (2006) (10.1128/JVI.00171-06) / J. Virol. by NA Wilson (2006)
  14. Friedrich, T. C. et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81, 3465–3476 (2007) (10.1128/JVI.02392-06) / J. Virol. by TC Friedrich (2007)
  15. Reynolds, M. R. et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205, 2537–2550 (2008) (10.1084/jem.20081524) / J. Exp. Med. by MR Reynolds (2008)
  16. Shen, A. et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77, 4938–4949 (2003) (10.1128/JVI.77.8.4938-4949.2003) / J. Virol. by A Shen (2003)
  17. Dinoso, J. B. et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83, 9247–9257 (2009) (10.1128/JVI.00840-09) / J. Virol. by JB Dinoso (2009)
  18. North, T. W. et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 84, 2913–2922 (2010) (10.1128/JVI.02356-09) / J. Virol. by TW North (2010)
  19. Ruiz, L. et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 13, F1–F8 (1999) (10.1097/00002030-199901140-00001) / AIDS by L Ruiz (1999)
  20. Blankson, J. N. et al. Isolation and characterization of replication-competent human immuno-deficiency virus type 1 from a subset of elite suppressors. J. Virol. 81, 2508–2518 (2007) (10.1128/JVI.02165-06) / J. Virol. by JN Blankson (2007)
  21. Anton, P. A. et al. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17, 53–63 (2003) (10.1097/00002030-200301030-00008) / AIDS by PA Anton (2003)
  22. Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. 12, Unit 12.11. (2005) (10.1002/0471142735.im1211s64)
  23. Cline, A. N., Bess, J. W., Piatak, M., Jr & Lifson, J. D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34, 303–312 (2005) (10.1111/j.1600-0684.2005.00128.x) / J. Med. Primatol. by AN Cline (2005)
  24. Venneti, S. et al. Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am. J. Pathol. 172, 1603–1616 (2008) (10.2353/ajpath.2008.070967) / Am. J. Pathol. by S Venneti (2008)
  25. Okoye, A. et al. Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis. J. Exp. Med. 206, 1575–1588 (2009) (10.1084/jem.20090356) / J. Exp. Med. by A Okoye (2009)
  26. Vaccari, M. et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J. Virol. 82, 9629–9638 (2008) (10.1128/JVI.00893-08) / J. Virol. by M Vaccari (2008)
  27. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29–43 (2002) (10.4049/jimmunol.168.1.29) / J. Immunol. by CJ Pitcher (2002)
  28. Veazey, R. S. et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427–431 (1998) (10.1126/science.280.5362.427) / Science by RS Veazey (1998)
  29. Schmitz, J. E. et al. Simian immunodeficiency virus (SIV)-specific CTL are present in large numbers in livers of SIV-infected rhesus monkeys. J. Immunol. 164, 6015–6019 (2000) (10.4049/jimmunol.164.11.6015) / J. Immunol. by JE Schmitz (2000)
  30. Chang, W. L. & Barry, P. A. Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. J. Virol. 77, 5073–5083 (2003) (10.1128/JVI.77.9.5073-5083.2003) / J. Virol. by WL Chang (2003)
  31. Kulkarni, V. R. et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine doi:10.1016/j.vaccine.2010.12.056. (10.1016/j.vaccine.2010.12.056) / Vaccine by Viraj Kulkarni (2011)
  32. Rosati, M. et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J. Virol. 79, 8480–8492 (2005) (10.1128/JVI.79.13.8480-8492.2005) / J. Virol. by M Rosati (2005)
  33. Rosati, M. et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc. Natl Acad. Sci. USA 106, 15831–15836 (2009) (10.1073/pnas.0902628106) / Proc. Natl Acad. Sci. USA by M Rosati (2009)
  34. Rosenfeld, M. A. et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143–155 (1992) (10.1016/0092-8674(92)90213-V) / Cell by MA Rosenfeld (1992)
  35. Mittereder, N., March, K. L. & Trapnell, B. C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498–7509 (1996) (10.1128/JVI.70.11.7498-7509.1996) / J. Virol. by N Mittereder (1996)
  36. Shen, A. et al. Novel pathway for induction of latent virus from resting CD4+ T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J. Virol. 81, 1660–1670 (2007) (10.1128/JVI.01396-06) / J. Virol. by A Shen (2007)
Dates
Type When
Created 14 years, 3 months ago (May 11, 2011, 4:39 a.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 1:51 p.m.)
Indexed 17 minutes ago (Sept. 3, 2025, 11:25 p.m.)
Issued 14 years, 4 months ago (May 1, 2011)
Published 14 years, 4 months ago (May 1, 2011)
Published Online 14 years, 3 months ago (May 11, 2011)
Published Print 14 years, 4 months ago (May 1, 2011)
Funders 0

None

@article{Hansen_2011, title={Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine}, volume={473}, ISSN={1476-4687}, url={http://dx.doi.org/10.1038/nature10003}, DOI={10.1038/nature10003}, number={7348}, journal={Nature}, publisher={Springer Science and Business Media LLC}, author={Hansen, Scott G. and Ford, Julia C. and Lewis, Matthew S. and Ventura, Abigail B. and Hughes, Colette M. and Coyne-Johnson, Lia and Whizin, Nathan and Oswald, Kelli and Shoemaker, Rebecca and Swanson, Tonya and Legasse, Alfred W. and Chiuchiolo, Maria J. and Parks, Christopher L. and Axthelm, Michael K. and Nelson, Jay A. and Jarvis, Michael A. and Piatak, Michael and Lifson, Jeffrey D. and Picker, Louis J.}, year={2011}, month=may, pages={523–527} }